Global Partners Lp (GLP)

Reports for Global Partners Lp

Global Partners Lp
GLP
10-07-2025
Read Report

Industries

Gas-Transportation
109002002
View Industry

Analysis

No analyses available for Global Partners Lp yet.

Latest News about Global Partners Lp

SALPHA
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
1750755040 | SALPHA
ZEROHEDGE
Hims & Hers Health Crashes After Novo Nukes GLP-1 Partnership Over "Illegal Mass Compounding" Scheme
1750683000 | ZEROHEDGE
BLOOMBERG
GLP-1s Should Be Treatment for Heart Disease, ACC Says
1750431580 | BLOOMBERG
BLOOMBERG
Trump Hints at Iran Delay, GLP-1s Get Heart Boost, More
1750429866 | BLOOMBERG
FORBES
Men Are Claiming Ozempic, GLP-1 Meds Are Making Their Genitals Bigger
1750116210 | FORBES
INVESTING
Eli Lilly's SWOT analysis: stock poised for growth amid challenges in GLP-1 market
1749931510 | INVESTING
ZEROHEDGE
Redburn Slaps McDonald's With Rare Downgrade As GLP-1 Drugs Reshape Consumer Habits
1749552900 | ZEROHEDGE
NASDAQ
CheqUp and WeightWatchers Partner to Enhance GLP-1 Weight Loss Solutions in the UK
1747894224 | NASDAQ
SALPHA
Pepsi: Forget GLP-1 And Dividend Cuts, These Are The Real Reasons Why It's Crashing
1747486800 | SALPHA
INVESTING
Fractyl Health Unveils New Rejuva ® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data...
1747481284 | INVESTING
INVESTING
How will GLP-1s impact the market for diabetes stocks? Berstein weighs in
1747479602 | INVESTING
BLOOMBERG
GLP-1 Drugs and TikTok Influencers Tipped Over WeightWatchers
1746889226 | BLOOMBERG
MWATCH
WeightWatchers goes bankrupt as offering GLP-1 drugs couldn’t cure debt problems
1746629880 | MWATCH
FORBES
‘Ozempic Mouth,’ ‘Feet’ Are Latest Names For GLP-1 Med Side Effects
1746383483 | FORBES
ZEROHEDGE
New GLP-1 Survey Finds Users Cutting Restaurant Spend
1746366900 | ZEROHEDGE
investors
CVS Stock Surges On Huge Q1 Beat Amid GLP-1 Deal With Novo Nordisk
1746106910 | investors
CNBC
GLP-1s can help employers lower medical costs in 2 years, new study finds
1746007201 | CNBC
BLOOMBERG
Singapore-Based GLP Debuts a $360 Million Data-Center Fund
1743566059 | BLOOMBERG
investors
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
1743170995 | investors
NASDAQ
OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist
1742252821 | NASDAQ
NASDAQ
Pre-Market Earnings Report for February 28, 2025 : GTLS, RDNT, FRO, APLS, AMRX, PAR, GLP, AMR,...
1740690001 | NASDAQ
FPOST
Ideal Protein Launches Whitepaper Unveiling Synergistic Approach to Enhance GLP-1 Medication Outcomes
1740684131 | FPOST
FORBES
The GLP-1 Revolution — Everyone And Their Moms Are On GLP-1s
1740535527 | FORBES
CNBC
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
1740436755 | CNBC
SALPHA
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
1740379529 | SALPHA
CNBC
Healthy Returns: Ozempic helps curb alcohol use in new study — and doctors are concerned about...
1739999042 | CNBC
NASDAQ
GLPG Crosses Above Key Moving Average Level
1739898658 | NASDAQ
HILL
Study finds rare vision issues in taking GLP-1 weight loss drugs
1739361957 | HILL
FPOST
CookUnity Unveils Chef-Made GLP-1 Balanced Meal Collection
1738706746 | FPOST
HILL
FDA approves GLP-1 generic for Type 2 diabetes
1735069738 | HILL
INVESTING
GLP-1: Barclays on why 2025 could be an inflection point
1734768000 | INVESTING
NASDAQ
DON, EVRG, GLPI, CNA: Large Outflows Detected at ETF
1734715571 | NASDAQ
ZEROHEDGE
Novo Nordisk Crashes Most On Record After CagriSema GLP-1 Results Disappoint
1734694943 | ZEROHEDGE
INVESTING
Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over
1734636315 | INVESTING
ZEROHEDGE
"Final Big Market Cap Event Of Year": All Eyes On Novo's CagriSema GLP-1 Results 
1734460800 | ZEROHEDGE
INVESTING
How we got to a global obesity epidemic and how GLP-1 is a game-changer
1734255000 | INVESTING
CNBC
Bernstein says Elon Musk's pro GLP-1 stance may boost Eli Lilly, sees nearly 40% upside
1734021186 | CNBC
NASDAQ
GLPI Dividend Yield Pushes Above 6%
1733516098 | NASDAQ
FORBES
GLP-1s Are Popular Obesity Meds, But What Role Could Prevention Play In Revamped HHS?
1733070898 | FORBES
INVESTING
Exclusive-Logistics provider GLP is considering a Hong Kong listing in 2025, sources say
1732864548 | INVESTING
FORBES
Employers May Follow Medicare Coverage Of GLP-1 Weight Loss Drugs
1732656329 | FORBES
FOX
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
1732624853 | FOX
NASDAQ
Guru Fundamental Report for GLPI
1732222800 | NASDAQ
NASDAQ
Interesting GLPI Put And Call Options For July 2025
1732119419 | NASDAQ
FOX
DR. MARC SIEGEL: Why Ozempic, Wegovy and other GLP-1s could be a magic shot against alcohol abuse
1732030953 | FOX
CNBC
Philippe Laffont’s Coatue makes big bets on China and GLP-1 drugmakers in latest quarter
1731623116 | CNBC
YAHOO
A new warning from the FDA for GLP1 drugs including Ozempic and Wegovy
1731078821 | YAHOO
INVESTING
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
1730985605 | INVESTING
BLOOMBERG
Move Over, GLP-1. New Obesity Treatments Are on the Way.
1730977230 | BLOOMBERG
SALPHA
Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
1730871478 | SALPHA
BLOOMBERG
GLP’s Canceled Bond Sale Shows Worries Over Finances Persist
1730680452 | BLOOMBERG
BLOOMBERG
GLP Pulls Dollar Bond Sale With Record Double-Digit Coupon
1730166691 | BLOOMBERG
Yahoo
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1...
1730040300 | Yahoo
BLOOMBERG
GLP’s Sale of Stake in China Operations Is Said to Have Stalled
1729854242 | BLOOMBERG
AG NEWS
Podcast - GLP-1 Drugs and Cultivated Meat: What’s the Impact on the Food and Agriculture Industry?
1729589588 | AG NEWS
BIZSTNDRD
Amneal Pharma to invest Rs 1,600 crore in Gujarat to make GLP-1 drugs
1728387951 | BIZSTNDRD
INVESTING
Analyst lifts ResMed stock outlook, citing wearables and GLP-1 prospects
1727702074 | INVESTING
BLOOMBERG
Ares Is Said in Advanced Talks on Deal With GLP Capital Partners
1726239673 | BLOOMBERG
CNBC
Digital health company Noom to offer compounded GLP-1 drug through new weight loss program
1726147985 | CNBC
CNBC
Digital health company Ro launches GLP-1 insurance-coverage checker to help patients navigate costs
1723554001 | CNBC
CNBC
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting...
1722337201 | CNBC
Yahoo
Wall Street is still jittery on GLP-1s
1722281466 | Yahoo
INVESTING
Earnings call: GLPI discusses Q2 2024 results and strategic moves
1722178876 | INVESTING
Yahoo
DexCom Stock Plunges 40% After Earnings. GLP-1s Weren’t the Problem.
1722001500 | Yahoo
SALPHA
Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
1720158172 | SALPHA
INVESTING
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body...
1719164405 | INVESTING
INVESTING
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a...
1719009604 | INVESTING
MWATCH
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
1718960100 | MWATCH
CNBC
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
1718629201 | CNBC
Yahoo
Eli Lilly unveils new manufacturing plant for GLP-1 pens
1718395688 | Yahoo
SALPHA
Structure Therapeutics: Yet Another Potential GLP-1 Entrant
1718375095 | SALPHA
FPOST
Ares Said to Explore Deal for Real Estate Investor GLP Capital Partners
1718288546 | FPOST
BLOOMBERG
Ares Explores Deal for Real Estate Investor GLP Capital Partners
1718287159 | BLOOMBERG
CNBC
Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
1717690720 | CNBC
CNBC
Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages
1716987601 | CNBC
CNBC
Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
1716566321 | CNBC
FPOST
Hydreight Technologies through its associated Medical network now offer Tirzepatide to Product...
1716462231 | FPOST
MWATCH
Amid ‘Ozempic babies’ questions, women account for more than 75% of young adults taking GLP-1...
1716390240 | MWATCH
INVESTING
Citi downgrades Hims & Hers stock citing GLP-1 launch risks
1716367835 | INVESTING
SALPHA
Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
1716293700 | SALPHA
CNBC
Nestle to launch Vital Pursuit frozen-food brand targeting GLP-1 users
1716291693 | CNBC
MWATCH
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
1716220860 | MWATCH
CNBC
Hims & Hers Health adds compounded GLP-1 injections to weight loss program
1716210049 | CNBC
MTLYFOOL
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
1715948640 | MTLYFOOL
INVESTING
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in...
1715837525 | INVESTING
ZEROHEDGE
1 In 8 US Adults Have Tried GLP-1 Obesity Medications, Poll Finds
1715725200 | ZEROHEDGE
INVESTING
Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows
1715363762 | INVESTING
BLOOMBERG
Logistics Firm GLP Says 2025 Bond Repayment Sources Identified
1714974323 | BLOOMBERG
BLOOMBERG
WeightWatchers Struggles to Adapt Amid GLP-1 Drug Boom
1714816831 | BLOOMBERG
BLOOMBERG
Blood Tests for Wegovy? Diagnostic Companies Target GLP-1s
1714644029 | BLOOMBERG
FPOST
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan...
1714568630 | FPOST
FPOST
Real Chemistry Introduces Iris: An Insights-as-a-Service Platform Delivering Timely Insights on...
1714475208 | FPOST
BLOOMBERG
Chinese State-Backed Firm Weighs Buying Major Stake in GLP China
1714449973 | BLOOMBERG